Advertisement

Abstract

The fatty acid-derived mediators of inflammation include arachidonic acid (AA), its 5-, 12- and 15-lipoxygenase (LO) metabolites (e.g., leukotrienes (LTs), mono-hydroxyeicosatetraenoic acids (HETEs) and lipoxins) and its cyclooxygenase (prostaglandin (PG)H synthetase) metabolites PGD2, PGE2, PGF, PGI2 and thromboxane (Tx) A2. These molecules possess many activities in a variety of systems and have been implicated as critical mediators in the pathophysiology of several diseases including some of the pulmonary system. In particular, significant attention has focused on the potential pivotal role of the cysteinyl or peptido leukotrienes (CysLTs: LTC4, LTD4, LTE4) and LTB4 in a variety of inflammatory disorders, notably asthma [1-3], arthritis [3–5] and inflammatory bowel disease (IBD) [3, 6–8]. The LTs produce a variety of effects in the respiratory system including smooth muscle contraction, enhanced mucus secretion [9, 10], inflammatory cell infiltration [11–13] and activation [11, 14], increased microvascular permeability [11, 15–17] and interactions with neuronal inputs [18], which may contribute to the etiology of pulmonary disorders. This chapter will focus on the ability of the LTs to contract airways smooth muscle and the signal transduction mechanisms and receptors involved in this action. In addition, the strategies pursued in the identification and development of drugs to control the release and effects of the LTs will be discussed, including a summary of the highlights of preclinical and clinical studies with representative compounds.

Keywords

Airway Smooth Muscle Allergy Clin Immunol Airway Smooth Muscle Contraction Airway Smooth Muscle Contractility LTD4 Receptor Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Drazen JM, Austen KF. Leukotrienes and Airway Responses. Am Rev Respir Dis 1987; 136: 985–998.PubMedGoogle Scholar
  2. 2.
    Piacentini GL, Kaliner MA. The potential roles of leukotrienes in bronchial asthma. Am Rev Respir Dis 1991; 143: S96–S99.PubMedGoogle Scholar
  3. 3.
    Summers JB. Inhibitors of leukotriene biosynthesis. Drug News and Perspectives 1990; 3: 517–526.Google Scholar
  4. 4.
    Davidson EM, Rae SA, Smith MJH. Leukotriene B4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis. Ann Rheum 1983; 42: 677–679.Google Scholar
  5. 5.
    Klickstein LB, Shapleigh C, Goetzl EJ. Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis. J Clin Invest 1980; 66: 1166–1170.PubMedGoogle Scholar
  6. 6.
    Sharon P, Stenson, WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984; 86: 453–460.PubMedGoogle Scholar
  7. 7.
    Staerk Laursen, L, Naesdal J, Bukhave K, Lauritsen K, Rask-Madsen J. Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet 1990; 335: 683–685.Google Scholar
  8. 8.
    Collawn C, Rubin P, Perez N, Bobadilla J, Cabrera G, Reyes E, et al. Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 342–346.PubMedGoogle Scholar
  9. 9.
    Marom Z, Shelhamer JH, Bach MK, Morton DR, Kaliner M. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982; 126: 449–451.PubMedGoogle Scholar
  10. 10.
    Hoffstein ST, Malo PE, Bugelski P, Wheeldon EB. Leukotriene D4 (LTD4) induces mucus secretion from goblet cells in the guinea pig respiratory epithelium. Exp Lung Res 1990; 16: 711–725.PubMedGoogle Scholar
  11. 11.
    Ford-Hutchinson AW. Leukotriene B4 in inflammation. Crit Rev Immunol 1990; 10:1–12.PubMedGoogle Scholar
  12. 12.
    Foster A, Chan CC. Peptide leukotriene involvement in pulmonary eosinophil migration upon antigen challenge in the actively sensitized guinea pig. Int Arch Allergy Appl Immunol 1991; 96: 279–284.PubMedGoogle Scholar
  13. 13.
    Laitinen L, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341: 989–990.PubMedGoogle Scholar
  14. 14.
    Henderson Jr WR. Eicosanoids and lung inflammation. Am Rev Respir Dis 1987; 135: 1176–1185.PubMedGoogle Scholar
  15. 15.
    Dahlén S-E, Björk J, Hedqvist P, Arfors K-E, Hammarström S, Lindgren J-A, et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: In vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci 1981; 78: 3887–3891.PubMedGoogle Scholar
  16. 16.
    Woodward DF, Weichman BM, Gill CA, Wasserman MA. The effect of synthetic leukotrienes on tracheal microvascular permeability. Prostaglandins 1983; 25: 131–142.PubMedGoogle Scholar
  17. 17.
    Joris I, Majno G, Corey EJ, Lewis RA. The mechanism of vascular leakage induced by leukotriene E4. Am J Pathol 1987; 126: 19–24.PubMedGoogle Scholar
  18. 18.
    Ellis JL, Undem BJ. Role of peptidoleukotrienes in capsaicin-sensitive sensory fibre-mediated responses in guinea-pig airways. J Physiol 1991; 436: 469–485.PubMedGoogle Scholar
  19. 19.
    Kellaway CH, Trethewie RE. The liberation of a slow reacting smooth muscle stimulating substance of anaphylaxis. Q J Exp Physiol 1940; 30: 121–145.Google Scholar
  20. 20.
    Brocklehurst WE. The release of histamine and slow reacting substance (SRS-A) during anaphylactic shock. J Physiol 1960; 151: 416–435.PubMedGoogle Scholar
  21. 21.
    Borgeat B, Samuelsson B. Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes. Formation of a novel dihydroxyeicosatetraenoic acid. J Biol Chem 1979; 254: 2643–2646.PubMedGoogle Scholar
  22. 22.
    Murphy RC, Hammarström S, Samuelsson B. Leukotriene C: A slow reacting substance from murine mastrocytoma cells. Proc Natl Acad Sci 1979; 76: 4275–4279.PubMedGoogle Scholar
  23. 23.
    Corey EJ, Clark DA, Goto G, Marfat A, Mioskowski C, Samuelsson B, Hammarström S. Stereospecific total synthesis of a “slow-reacting substance of anaphylaxis” (SRS-A), leukotriene C-1. J Am Chem Soc 1980; 102: 1436–1439.Google Scholar
  24. 24.
    Radmark D, Malmsten C, Samuelsson B, Leukotriene A4 enzymatic conversion to leukotriene C4. Biochem Biophys Res Commun 1980; 96: 1679–1687.PubMedGoogle Scholar
  25. 25.
    Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220: 568–575.PubMedGoogle Scholar
  26. 26.
    Verheij HM, Slotboom AJ, de Haas GH. Structure and function of phospholipase A2. Rev Physiol Biochem Pharmacol 1981; 9: 191–203.Google Scholar
  27. 27.
    Dennis EA. Phospholipases. In: Boyer PD, editor. The Enzymes. Lipid Enzymology, vol. 16. New York: Academic Press, 1983: 307–353.Google Scholar
  28. 28.
    Vadas P, Pruzanski W. Role of secretory phospholipase A2 in the pathology of disease. Lab Invest 1986; 55: 391–404.PubMedGoogle Scholar
  29. 29.
    Chang HW, Kudo I, Tomita M, Inoue K. Purification and characterization of extracellular phospholipase A2 from peritoneal cavity of caseinate-treated rat. J Biochem 1987; 102: 147–154.PubMedGoogle Scholar
  30. 30.
    Dixon RAF, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, Gillard JW, Miller DK. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990; 343: 282–284.PubMedGoogle Scholar
  31. 31.
    Miller DK, Gillard JW, Vickers PJ, Sadowski S, Léveillé C, Mancini JA, Charleson P, Dixon RAF, Ford-Hutchinson AW, Fortin R, Gauthier JY, Rodkey J, Rosen R, Rouzer C, Sigal IS, Strader CD, Evans JF. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990; 343: 278–281.PubMedGoogle Scholar
  32. 32.
    Evans JF, Léveillé C, Mancini JA, Prasit P, Thérien M, Zamboni R, Gauthier JY, Fortin R, Charleson P, MacIntyre DE, Luell S, Bach TJ, Meurer R, Guay J, Vickers PJ, Rouzer CA, Gillard JW, Miller DL. 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors. Mol Pharmacol 1991; 40: 22–27.PubMedGoogle Scholar
  33. 33.
    Ford-Hutchinson AW. FLAP: a novel drug target for inhibiting the synthesis of leukotrienes. Trends Pharmacol Sci 1991; 12: 68–70.PubMedGoogle Scholar
  34. 33a.
    Abramovitz M, Wong E, Cox ME, Richardson CD, Li C, Vickers PJ. 5-Lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur J Biochem 1993; 215: 105–111.PubMedGoogle Scholar
  35. 33b.
    Mancini JA, Abramovitz M, Cox ME, Wong E, Charleson S, Perrier H, et al. 5-Lipoxygenase-activating protein is an arachidonate binding protein. FEBS 1993; 318: 277–281.Google Scholar
  36. 34.
    Hammarström S. Leukotrienes. Ann Rev Biochem 1983; 52: 355–377.PubMedGoogle Scholar
  37. 35.
    Samuelsson B, Dahlén S-E, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 137: 1171–1176.Google Scholar
  38. 36.
    Mobilio D, Marshall LA. Recent advances in the design and evaluation of inhibitors of phospholipase A2. Ann Rep Med Chem 1989; 24: 157–165.Google Scholar
  39. 37.
    Glaser KB, Mobilio D, Chang JY, Senko N. Phospholipase A2 enzymes: regulation and inhibition. Trends Pharmacol Sci 1993; 141: 92–98.Google Scholar
  40. 38.
    Marshall LA, Chang JY. Pharmacological control of phospholipase A2. activity in vitro and in vivo. In: Wong PY-K, Dennis EA, editors. Phospholipase A2. New York: Plenum Press, 1990: 169–182.Google Scholar
  41. 39.
    Jacobs RS, Culver P, Langdon R, O’Brien T, White S. Some pharmacological observations on marine natural products. Tetrahedron 1985; 41: 981–984.Google Scholar
  42. 40.
    Sommers CD, Bobbitt JL, Bemis KG, Snyder DW. Porcine pancreatic phospholipase A2-induced contractions of guinea pig lung pleural strips. Eur J Pharmacol 1992; 216: 87–96.PubMedGoogle Scholar
  43. 41.
    Strek ME, Garland A, Abrahams C, Leff AR, White SR. Direct effects and augmentation of airway smooth muscle contraction caused by phospholipase A2. Am Rev Respir Dis 1992; 145: 1463–1468.PubMedGoogle Scholar
  44. 42.
    Miyake A, Yamamoto H, Takebayashi Y, Imai H, Honda K. The novel natural product YM 26567-1 [(+)-trans-4-(3-dodecanoyl-2,4,6-trihydroxyphenyl)-7-hydroxy-2-(4-hydroxyphenyl)chroman]: a competitive inhibitor of group II phospholipase A2. J Pharmacol Exp Ther 1992; 263: 1302–1307.PubMedGoogle Scholar
  45. 43.
    LeMahieu RA, Carson M, Han R-J, Madison VS, Hope WC, Chen T, Morgan DW, Hendrickson HS. N-(Carboxymethyl)-N-[3,5-bis(decyloxy)-phenyl]glycine (Ro 23-9358): a potent inhibitor of secretory phospholipases A2 with antiinflammatory activity. J Med Chem 1993; 36: 3029–3031.PubMedGoogle Scholar
  46. 44.
    Beaton HG, Bennion C, Connolly S, Cook AR, Gensmantel NP, Hallam C, et al. Discovery of new non-phospholipid inhibitors of the secretory phospholipases A21. J Med Chem 1994; 37: 557–559.PubMedGoogle Scholar
  47. 45.
    Ford-Hutchinson AW. Inhibition of leukotriene biosynthesis. Ann NY Acad Sci 1991; 629: 133–142.PubMedGoogle Scholar
  48. 46.
    McMillan RM, Walker ERH. Designing therapeutically effective 5-lipoxygenase inhibitors. Trends Pharmacol Sci 1992; 131: 323–330.Google Scholar
  49. 47.
    Musser JH, Kreft AF. 5-Lipoxygenase: properties, pharmacology, and the quinolinyl-(bridged)aryl class of inhibitors. J Med Chem 1992; 14: 2501–2524.Google Scholar
  50. 48.
    Hand JM, Schwalm SF, Lewis AJ. Antagonism of antigen-induced contraction of isolated guinea-pig trachea by 5-lipoxygenase inhibitors. Int Arch Allergy Appl Immunol 1986; 79: 8–13.PubMedGoogle Scholar
  51. 49.
    McFarlane CS, Hamel R, Ford-Hutchinson AW. Effects of a 5-lipoxygenase inhibitor (L-651,392) on primary and late pulmonary responses to ascaris antigen in the squirrel monkey. Agents Actions 1987; 22: 63–68.PubMedGoogle Scholar
  52. 50.
    Piechuta H, Rokach J, Williams H, Young RN, DeHaven RN, Pong SS. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 1989; 67: 17–28.Google Scholar
  53. 51.
    Johnson HG, Stout BK. Activity of a novel hydroquinone inhibitor of leukotriene synthesis (U-66,858) in the rhesus monkey Ascaris reactor. Int Arch Allergy Appl Immunol 1988; 87: 204–207.PubMedGoogle Scholar
  54. 52.
    Payne AN, Garland LG, Lees IW, Salmon JA. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: effects on bronchial anaphylaxis in anaesthetized guinea-pigs. Br J Pharmacol 1988; 94: 540–546.PubMedGoogle Scholar
  55. 53.
    Yamamura H, Taira M, Negi H, Nanbu F, Kohno SW, Ohata K. Effect of AA-861, a selective 5-lipoxygenase inhibitor, on models of allergy in several species. Jap J Pharmacol 1988; 47: 261–271.PubMedGoogle Scholar
  56. 54.
    Wegner CD, Gundel RH, Abraham WM, Schulman ES, Kontny MJ, Lazer ES, Homon CA, Graham AG, Torcellini CA, Clarke CC, Jager P, Wolyniec WW, Letts G, Farine PR. The role of 5-lipoxygenase products in preclinical models of asthma. J Allergy Clin Immunol 1993; 91: 917–929.PubMedGoogle Scholar
  57. 55.
    Yeadon M, Dougan FL, Petrovic A, Beesley JE, Payne AN. Effect of BW B70C, a novel inhibitor of arachidonic acid 5-lipoxygenase, on allergen-induced bronchoconstriction and late-phase lung eosinophil accumulation in sensitised guinea-pigs. Agents Actions 1993; 38: 8–18.PubMedGoogle Scholar
  58. 56.
    Malo PE, Bell RL, Shaughnessy TK, Summers JB, Brooks DW, Cater GW. The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis. Pulm Pharmacol 1994; 7: 73–79.PubMedGoogle Scholar
  59. 57.
    Adams III GK, Lichtenstein L. In vitro studies of antigen-induced bronchospasm: effect of antihistamine and SRS-A antagonist on response of sensitized guinea pig and human airways to antigen. J Immunol 1979; 122: 555–562.PubMedGoogle Scholar
  60. 58.
    Dahlén S-E, Hansson G, Hedqvist P, Björck T, Granström E, Dahlén B. Allergen challenge on lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4 and E4. Proc Natl Acad Sci 1983; 80: 1712–1716.PubMedGoogle Scholar
  61. 59.
    Hay DWP, Muccitelli RM, Tucker SS, Vickery-Clark LM, Wilson KA, Gleason JG, Hall RF, Wasserman MA, Torphy TJ. Pharmacological profile of SK&F 104353: a novel potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways. J Pharmacol Exp Ther 1987; 243: 474–481.PubMedGoogle Scholar
  62. 60.
    Björk T, Dahlén S-E. Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: pharmacological evidence obtained with tissues from asthmatic and non-asthmatic subjects. Pulm Pharmacol 1993; 6: 87–96.Google Scholar
  63. 61.
    Carter GW, Young PR, Albert DH, Bouska JB, Dyer RD, Bell RL, Summers JB, Brooks DW, Gunn BP, Rubin P, Kesterson J. Leukotrienes and Prostanoids in Health and Disease. In: Zor U, Naor Z, Danon A, editors. New Trends Lipid Mediators Research vol. 3. Basel: Karger, 1989: 50–55.Google Scholar
  64. 62.
    Bell RL, Young PR, Albert D, Lanni C, Summers JB, Brooks DW, Rubin P, Carter GW. The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. Int J Immunopharmacol 1992; 14: 505–510.PubMedGoogle Scholar
  65. 63.
    Rubin P, Dubt L, Braleckman R, Swanson L, Hansen R, Albert D, Carter G. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase. Agents Actions 1991; 35: 103–116.Google Scholar
  66. 64.
    Hui KP, Taylor IK, Taylor GW, Rubin P, Kesterson J, Barnes NC, Barnes PJ. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991; 46: 184–189.PubMedGoogle Scholar
  67. 65.
    Israel E, Dermarkarian R, Rosenberg M, Sperling R, Taylor G, Rubin P, Drazen JM. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. New Eng J Med 1990; 323: 1740–1744.PubMedGoogle Scholar
  68. 66.
    Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, Tinkelman D, Murray JJ, Busse W, Segal AT, Fish J, Kaiser HB, Ledford D, Wenzel S, Rosenthal R, Cohn J, Lanni C, Pearlman H, Karahalios P, Drazen JM. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119: 1059–1066.PubMedGoogle Scholar
  69. 67.
    Israel E, Fischer AR, Rosenberg MS, Lilly CM, Callergy JC, Shapiro J, Cohn J, Rubin P, Drazen JM. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447–1451.PubMedGoogle Scholar
  70. 68.
    Tateson JE, Randall RW, Reynolds CH, Jackson WP, Bhattacherjee P, Salmon JA, Garland LG. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo. Br J Pharmacol 1988; 94: 528–539.PubMedGoogle Scholar
  71. 69.
    Spencer DA, Sampson AP, Evans JM, Garland LG, Piper PJ, Costello JF. The effects of a 5-lipoxygenase inhibitor, BW A4C, on the acute response to inhaled PAF in man. Ann NY Acad Sci 1991; 629: 430–431.PubMedGoogle Scholar
  72. 70.
    Fujimura M, Sasaki F, Nakatsumi Y, Takahashi Y, Hifumi S, Taga K, Mifune J-I, Tanaka T, Matsuda T. Effects of a thromboxane synthetase inhibitor (OKY-046) and a lipoxygenase inhibitor (AA-861) on bronchial responsiveness to acetylcholine in asthmatic subjects. Thorax 1986; 41: 955–959.PubMedGoogle Scholar
  73. 71.
    Gillard J, Ford-Hutchinson AW, Chan C, Charleson S, Denis D, Foster A, Fortin R, Leger S, McFarlane CS, Morton H, Piechuta H, Riendeau D, Rouzer CA, Rokach J, Young R, MacIntyre DE, Peterson L, Bach T, Eiermann G, Hopple S, Humes J, Hupe L, Luell S, Metzger J, Meurer R, Miller DK, Opas E, Pacholok S. L-663,356 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2,-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol 1989; 67: 456–464.PubMedGoogle Scholar
  74. 72.
    Bfideau C, Chan C, Charleson S, Denis D, Evans JF, Ford-Hutchinson AW, Fortin R, Gillard JW, Guay J, Guévremont D, Hutchinson JH, Jones TR, Leger S, Mancini JA, McFarlane CS, Pickett C, Piechuta H, Prasit P, Riendeau D, Rouzer CA, Tagari P, Vickers PJ, Young RN. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol 1992; 70: 799–807.Google Scholar
  75. 73.
    Friedman BS, Bel EH, Buntinx A, Tanaka W, Han Y-HR, Shingo S, Spector R, Sterk P. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev. Respir Dis 1993; 147: 839–844.PubMedGoogle Scholar
  76. 74.
    Ishida K, Thomson KJ, Schellenberg RR. Role of leukotrienes in airway hyperresponsiveness in guinea-pigs. Br J Pharmacol 1993; 108: 70–704.Google Scholar
  77. 75.
    Krell RD, Osborn R, Vickery L, Falcone K, O’Donnell M, Gleason J, Kinzig C, Bryan D. Contraction of isolated airway smooth muscle by synthetic leukotrienes C4 and D4. Prostaglandins 1981; 22: 387–409.PubMedGoogle Scholar
  78. 76.
    Snyder DW, Krell RD. Pharmacological evidence for a distinct leukotriene C4 receptor in guinea-pig trachea. J Pharmacol Exp Ther 1984; 231: 616–622.PubMedGoogle Scholar
  79. 77.
    Raeburn D, Rodger IW. Lack of effect of leukotriene D4 on Ca-uptake in airway smooth muscle. Br J Pharmacol 1984; 83: 499–504.PubMedGoogle Scholar
  80. 78.
    Weichman BM, Tucker SS. Differentiation of the mechanisms by which leukotrienes C4 and D4 elicit contraction of the guinea pig trachea. Prostaglandins 1984; 29: 547–560.Google Scholar
  81. 79.
    Buckner CK, Fedyna JS, Robertson JL, Will JA, England DM, Krell RD, Saban R. An examination of the influence of the epithelium on contractile responses to peptidoleukotrienes and blockade by ICI 204,219 in isolated guinea pig trachea and human intralobar airways. J Pharmacol Exp Ther 1990; 252: 77–85.PubMedGoogle Scholar
  82. 80.
    Hay DWP, Muccitelli RM, Vickery-Clark LM, Novak LS, Osborn RR, Gleason JG, Yodis L-AP, Saverino SM, Eckardt RD, Sarau HM, Wasserman MA, Torphy TJ, Newton JF. Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pig. Pulm Pharmacol 1991; 4: 177–189.PubMedGoogle Scholar
  83. 81.
    Daniel EE, Abela AP, Janssen LJ, O’Byrne PM. Effects of inflammatory mediators on canine airway neuromuscular function. Can J Physiol Pharmacol 1992; 70: 624–634.PubMedGoogle Scholar
  84. 82.
    Abela A, Daniel EE. Neural and myogenic effects of leukotrienes C4, D4 and E4 on canine bronchial smooth muscle. Am J Physiol 1994; 266: L414–L425.PubMedGoogle Scholar
  85. 83.
    Ishihara Y, Sheller J. Effect of leukotrienes on sheep airway smooth muscle. J Lipid Mediators 1993; 7: 47–56.Google Scholar
  86. 84.
    Doucet MY, Jones TR, Ford-Hutchinson AW. Responses of equine trachealis and lung parenchyma to methacholine, histamine, serotonin, prostanoids, and leukotrienes in vitro. Can J Physiol Pharmacol 1990; 68: 379–383.PubMedGoogle Scholar
  87. 85.
    Snyder DW, Krell RD. Pharmacology of peptide leukotrienes on ferret isolated airway smooth muscle. Prostaglandins 1986; 32: 189–200.PubMedGoogle Scholar
  88. 86.
    Roberts JA, Giembycz MA, Raeburn D, Rodger IW, Thomson NC. In vitro and in vivo effect of verapamil on human airway responsiveness to leukotriene D4. Thorax 1986; 41: 12–16.PubMedGoogle Scholar
  89. 87.
    Buckner CK, Krell RD, Laravuso RB, Coursin DB, Bernstein PR, Will JA. Pharmacological evidence that human intralobar airways do not contain different receptors that mediate contractions to leukotriene C4 and leukotriene D4. J Pharmacol Exp Ther 1986; 237: 558–562.PubMedGoogle Scholar
  90. 88.
    Cristol JP, Provencal B, Sirois P. Leukotriene receptors. J Receptor Res 1989; 9: 341–367.Google Scholar
  91. 89.
    Crooke ST, Sarau H, Saussy D, Winkler J, Foley J. Signal transduction processes for the LTD4 receptor. Adv Prostaglandin Thromboxane Leukotriene Res 1990; 20: 127–137.Google Scholar
  92. 90.
    Krell RD, Aharony D, Buckner CK, Kusner EJ. Peptide leukotriene receptors and antagonists. In: Samuelsson B, Dahlén SE, Fritsch J, Hedqvist P, editors. Advances in Prostaglandin, Thromboxane, and Leukotriene Research, vol. 20. New York: Raven Press, Ltd., 1990: 119–126.Google Scholar
  93. 91.
    Norman P, Abram TS, Kluender HC, Gardiner PJ, Cuthbert NJ. The binding of [3H]leukotriene C4 to guinea-pig lung membranes. The lack of correlation of LTC4 functional activity with binding affinity. Eur J Pharmacol 1987; 143: 323–334.PubMedGoogle Scholar
  94. 92.
    Sun FF, Chau LY, Austen KF. Binding of leukotriene C4 by glutathione transferase: a reassessment of biochemical and functional criteria for leukotriene receptors. Fed Proc 1987; 46: 204–207.PubMedGoogle Scholar
  95. 93.
    Goffinet AM, Nguyen A. Brain leukotriene C4 binding sites are S-alkylglutathione binding sites. Eur J Pharmacol 1989; 161: 99–101.PubMedGoogle Scholar
  96. 94.
    Mong S, Hoffman K, Wu H-L, Crooke ST. Leukotriene-induced hydrolysis of inositol lipids in guinea-pig lung: mechanism of signal transduction for leukotriene-D4 receptors. Mol Pharmacol 1987; 31: 35–41.PubMedGoogle Scholar
  97. 95.
    Hay DWP, Muccitelli RM, Wilson KA, Wasserman MA, Torphy TJ. Functional antagonist by salbutamol suggests differences in the relative efficacies and dissociation constants of the peptidoleukotrienes in guinea pig trachea. J Pharmacol Exp Ther 1987; 244: 71–78.Google Scholar
  98. 96.
    Jones TR, Zamboni R, Belley M, Champion E, Charette L, Ford-Hutchinson AW, Frenette R, Gauthier J-Y, Leger S, Masson P, McFarlane CS, Piechuta H, Rokach J, Williams H, Young RN, DeHaven RN and Pong SS. Pharmacology of L-660,711 (MK-571): a novel potent and selective, leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 1989; 67: 17–28.PubMedGoogle Scholar
  99. 97.
    Aharony D, Catanese CA, Falcone RC. Kinetic and pharmacologic analysis of [3H]leukotriene E4 binding to receptors on guinea pig lung membranes: evidence for selective binding to a subset of leukotriene D4 receptors. J Pharmacol Exp Ther 1989; 248: 581–588.PubMedGoogle Scholar
  100. 98.
    Labat C, Ortiz JL, Norel X, Gorenne I, Verley J, Abram TS, Cuthbert NJ, Tudhope SR, Norman P, Gardiner P, Brink C. A second cysteinyl leukotriene receptor in human lung. J Pharmacol Exp Ther 1992; 263: 800–805.PubMedGoogle Scholar
  101. 99.
    Mong S, Scott MO, Lewis MA, Wu H-L, Hogaboom GK, Clark MA, Crooke ST. Leukotriene E4 binds specifically to LTD4 receptors in guinea pig lung membranes. Eur J Pharmacol 1985; 109: 183–192.PubMedGoogle Scholar
  102. 100.
    Mong S, Hoffman K, Wu H-L, Crooke ST. Leukotriene-induced hydrolysis of inositol lipids in guinea pig lung: Mechanism of signal transduction for leukotriene-D4 receptors. Mol Pharmacol 1987; 31: 35–41.PubMedGoogle Scholar
  103. 101.
    Sturton RG, Hammond MD. 6th International Conference on Prostaglandins, Leukotrienes and Related Compounds. New York: Raven Press, 1986: 142.Google Scholar
  104. 102.
    Mong S, Miller J, Wu H-L, Crooke ST. Leukotriene D4 receptor-mediated hydrolysis of phosphoinositide and mobilization of calcium in sheep tracheal smooth muscle cells. J Pharmacol Exp Ther 1988; 244: 508–515.PubMedGoogle Scholar
  105. 103.
    Lewis MA, Mong S, Vessella RL, Crooke ST. Identification and characterization of leukotriene D4 receptors in adult and fetal human lung. Biochem Pharmacol 1985; 34: 4311–4317.PubMedGoogle Scholar
  106. 104.
    Rovati GE, Giovanazzi SG, Mezzetti M, Nicosia S. Heterogeneity of binding sites for ICI 198,615 in human lung parenchyma. Biochem Pharmacol 1992; 44: 1411–1415.PubMedGoogle Scholar
  107. 105.
    Bouchelouche PN, Ahnfelt-Rønne I, Thomsen MK. LTD4 increases cytosolic free calcium and inositol phosphates in human neutrophils: inhibition by the novel LTD4 receptor antagonist, SR2640, and possible relation to modulation of chemotaxis. Agents Actions 1990; 29: 299–307.PubMedGoogle Scholar
  108. 106.
    Mong S, Wu H-L, Wong A, Sarau HM, Crooke ST. LTD4 receptor-mediated phosphoinositol hydrolysis and calcium mobilization in rat basophilic leukemic cells. J Pharmacol Exp Ther 1988; 247: 803–813.PubMedGoogle Scholar
  109. 107.
    Sarau HM, Mong S, Foley JJ, Wu H-L, Crooke ST. Identification and characterization of leukotriene D4 receptors and signal transduction processes in rat basophilic leukemia cells. J Biol Chem 1987; 262: 4034–4041.PubMedGoogle Scholar
  110. 108.
    Howard S, Chan-Yeung M, Martin L, Phaneuf S, Salari H. Polyphosphoinositide hydrolysis and protein kinase C activation in guinea-pig tracheal smooth muscle cells in culture by leukotriene D4 involve a Pertussis toxin sensitive G-protein. Eur J Pharmacol — Mol Pharmacol Section 1992; 227: 123–129.Google Scholar
  111. 109.
    Piper PJ, Samhoun MN. Stimulation of arachidonic acid metabolism and generation of thromboxane A2 by leukotrienes B4, C4 and D4 in guinea-pig lung in vitro. Br J Pharmacol 1982; 77: 267–275.PubMedGoogle Scholar
  112. 110.
    Weichman BM, Muccitelli RM, Osborn RR, Holden DA, Gleason JG, Wasserman MA. In vitro and in vivo mechanisms of leukotriene-mediated bronchoconstriction in the guinea pig. J Pharmacol Exp Ther 1982; 222: 202–208.PubMedGoogle Scholar
  113. 111.
    Andersson RGG, Gustafsson LE, Hedman SE, Hedqvist P, Samuelsson B. Leukotriene C4-induced cyclic nucleotide changes and contractile responses in guinea-pig trachea. Acta Physiol Scand 1982; 116: 97–99.PubMedGoogle Scholar
  114. 112.
    Andersson RGG, Hedman SE, Hultgren A. Leukotrienes, leukotriene-receptive substances and the cyclic AMP system of guinea-pig airways. Adv Cyclic Nucl Protein Phosphorylation Res 1983; 17A: 117.Google Scholar
  115. 113.
    Barnes PJ, Grandordy B. Leukotriene C4 elicits inositol phosphate formation and inhibits adenylate cyclase in guinea-pig lung. Br J Pharmacol 1986; 89: 783P.Google Scholar
  116. 114.
    Hedman SE, Andersson RGG. Effect of SRS (slow reacting substance) on cyclic nucleotides in guinea pig tracheal muscle. Acta Pharmacol Toxicol 1982; 50: 30–34.Google Scholar
  117. 115.
    Hedman SE, Andersson RGG. The cyclic AMP system in sensitized and desensitized guinea-pig tracheal smooth muscle. Eur J Pharmacol 1982; 83: 107–112.PubMedGoogle Scholar
  118. 116.
    Giembycz MA, Diamond J, Rodger IW. Leukotriene D4 receptors are not negatively coupled to adenylyl cyclase in guinea-pig lung parenchyma. Br J Pharmacol 1993; 108: 824–832.PubMedGoogle Scholar
  119. 117.
    Langlands JM, Rodger IW, Watson J. Effect of methacholine and leukotriene D4 on cyclic AMP content and cyclic AMP-dependent protein kinase activity in airway smooth muscle. Br J Pharmacol 1987; 92: 633P.Google Scholar
  120. 118.
    Augstein J, Farmer JB, Lee TB, Sheard P, Tattersall ML. Selective inhibition of slow reacting substance of anaphylaxis. Nature 1973; 245: 215–216.Google Scholar
  121. 119.
    Chand N. FPL-55712 — an antagonist of slow reacting substance of anaphylaxis (SRS-A): A review. Agents Actions 1979; 9: 133–140.PubMedGoogle Scholar
  122. 120.
    Fleisch JH, Rinkema LE, Haisch KD, McCullough D, Carr FP, Dillard RD. Evaluation of LY 163443, 1-[2-hydroxy-3-propyl-4-[4-(1H-tetrazol-5-ylmethyl)phenoxy]methyl-phenyljethanone, as a pharmacologic antagonist of leukotrienes D4 and E4. Naunyn-Schmied Arch Pharmacol 1986; 333: 70–77.Google Scholar
  123. 121.
    Adaikan PG, Lau LC, Kottegoda SR, Ratnam SS. Effects of two new leukotriene antagonists ONO-RS-347 and ONO-RS-411 (ONO-1078) on the guinea pig and human respiratory and other systems. In: Samuelsson B, Paoletti R, Ramwell PW, editors. Advances in Prostaglandins, Thromboxane, and Leukotriene Research, vol. 17. New York: Raven Press, 1987: 549–553.Google Scholar
  124. 122.
    Obata T, Nambu F, Kitagawa T, Terashima H, Toda M, Okegawa T, Kawasaki A. ONO-1078: An antagonist of leukotrienes. In: Samuelsson B, Paoletti R, Ramwell PW, editors. Advances in Prostaglandins, Thromboxane, and Leukotriene Research, vol. 17. New York: Raven Press, 1987: 540–542.Google Scholar
  125. 123.
    Snyder DW, Giles RE, Keith RA, Yee YK, Krell RD. In vitro pharmacology of ICI 198,615: A novel, potent and selective peptide leukotriene antagonist. J Pharmacol Exp Ther 1987; 243: 548–556.PubMedGoogle Scholar
  126. 124.
    Ahnfelt-Rønne I, Kirstein D, Kaergaard-Nielsen C. A novel leukotriene D4/E4 antagonist, SR2640 (2-[3-(2-quinolylmethoxy)phenylamino]benzoic acid). Eur J Pharmacol 1988; 155: 117–128.PubMedGoogle Scholar
  127. 125.
    Boot JR, Bond A, Gooderham R, O’Brien A, Parsons M, Thomas KH. The pharmacological evaluation of LY17060, a novel leukotriene D4 and E4 antagonist in the guinea-pig. Br J Pharmacol 1989; 98: 259–267.PubMedGoogle Scholar
  128. 126.
    Hand JM, Auen MA, Chang J, Englebach IM. Prevention of aerosol LTD4-induced changes in guinea pig pulmonary mechanics by Wy-48252, an orally active LTD4/E4 receptor antagonist. Int Arch Allergy Appl Immunol 1989; 89: 78–82.PubMedGoogle Scholar
  129. 127.
    Hand JM. Schwalm SF, Auen MA, Kreft AF, Musser JH, Chang J. WY-48,252 (1,1,1-trifluoro-N-[3-(2-quinolinylmethoxy)phenyl]methane sulfonamide) an orally active leukotriene D4 antagonist: Pharmacological characterization in vitro and in vivo in the guinea pig. Prostaglandins, Leukotrienes and Essential Fatty Acids 1989; 37: 97–106.Google Scholar
  130. 128.
    Krell RD, Kusner EJ, Aharony D, Giles RE. Biochemical and pharmacological characterization of ICI 198,615: a peptide leukotriene receptor antagonist. Eur J Pharmacol 1989; 159: 73–81.PubMedGoogle Scholar
  131. 129.
    Krell RD, Aharony D, Buckner CK, Keith RA, Kusner EJ, Snyder DW, Bernstein PR, Matassa VG, Yee YK, Brown FJ, Hesp B, Giles RE. The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist. Am Rev Respir Dis 1990; 141: 978–987.PubMedGoogle Scholar
  132. 130.
    Van Inwegen RG, Nuss GW, Carnathan GW. Antagonism of peptidoleukotrienes and inhibition of systematic anaphylaxis by RG 12525 in guinea pigs. Life Sci 1989; 44: 799–807.PubMedGoogle Scholar
  133. 131.
    Ishii A, Nakagawa T, Nambu F, Motoishi M, Miyamoto T. Inhibition of endogenous leukotriene-mediated lung anaphylaxis in guinea pigs by a novel receptor antagonist ONO-1078. Int Arch Allergy Appl Immunol 1990; 92: 404–407.PubMedGoogle Scholar
  134. 132.
    Bray MA, Anderson WH, Subramanian N, Niederhauser U, Kuhn M, Erard M, von Sprecher A. CGP 45715: A leukotriene D4 analogue with potent peptido-LT antagonist activity. In: Samuelsson B, Ramwell PW, Paoletti R, Folco G, Granström E, editors. Advances in Prostaglandin, Thromboxane, and Leukotriene Research, vol. 21B. New York: Raven Press, Ltd., 1991: 503–507.Google Scholar
  135. 133.
    O’Donnell M, Crowley HJ, Yaremko B, O’Neill N, Welton, AF. Pharmacologic actions of Ro 24-5913, a novel antagonist of leukotriene D4. J Pharmacol Exp Ther 1991; 259: 751–758.PubMedGoogle Scholar
  136. 134.
    Abram TS, Böshagen H, Butler JE, Cuthbert NJ, Francis HP, Gardiner PJ, Hartwig W, Kluender HC, Norman P, Meier H, Rosentreter U, Schlemmer KH, Tudhope SR, Taylor WA. A new structural analogue antagonist of peptidoleukotrienes. The discovery of BAY x7195. Bioorganic Med Chem Lett 1993; 3: 1517–1522.Google Scholar
  137. 135.
    Goldman DW, Gifford LA, Marotti T, Koo CH, Goetzl EJ. Molecular and cellular properties of human polymorphonuclear leukocyte receptors for leukotriene B4. Fed Proc 1987; 46: 200–203.PubMedGoogle Scholar
  138. 136.
    Sofia MJ, Saussy Jr DL, Jackson WT, Marder P. Silbaugh SA, Froelich LL, Cockerham SL, Stengel PW. Ortho-alkoxyphenol leukotriene B4 receptor antagonists: effect of a chroman carboxylic acid. Bioorganic Med Chem Lett 1992; 2: 1675–1680.Google Scholar
  139. 137.
    Goldman DW, Gifford LA, Young RN, Marotti T, Cheung MKL, Goetzl EJ. Affinity labeling of the membrane protein-binding component of human polymophonuclear leukocyte receptors for leukotriene B4. J Immunol 1991; 146: 2671–2677.PubMedGoogle Scholar
  140. 138.
    Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJH. Leukotriene B: a potent and aggregating substance released from polymorphonuclear leukocytes. Nature 1980; 286: 264–265.PubMedGoogle Scholar
  141. 139.
    Bray MA. The pharmacology and pathophysiology of leukotriene B4. Br Med Bull 1983; 39: 249–254.PubMedGoogle Scholar
  142. 140.
    Thorsen S. Leukotriene B4, a mediator of inflammation. Scand J Rheumatol 1986; 15: 225–236.PubMedGoogle Scholar
  143. 141.
    Rae SA, Smith MJH. The stimulation of lysosomal enzyme secretion from human polymorphonuclear leucocytes by leukotriene B4. J Pharm Pharmacol 1981; 33: 616–617.PubMedGoogle Scholar
  144. 142.
    Serhan CN, Radin A, Smolen JE, Korchak H, Samuelsson B, Weissmann G. Leukotriene B4 is a complete secretagogue in human neutrophils: a kinetic analysis. Biochem Biophys Res Commun 1982; 107: 1006–1012.PubMedGoogle Scholar
  145. 143.
    Gimbrone MA Jr, Brock AF, Schafe AI. Leukotriene B4 stimulates polymorphonuclear leukocyte adhesion to cultured vascular endothelial cells. J Clin Invest 1984; 74: 1552–1555.PubMedGoogle Scholar
  146. 144.
    Hoover RL, Kamovsky MJ, Austen KF, Corey EJ, Lewis RA. Leukotriene B4 action on endothelium mediates augmented neutrophil/endothelial adhesion. Proc Natl Acad Sci 1984; 81: 2191–2193.PubMedGoogle Scholar
  147. 145.
    Morris J, Wishka DG. Synthesis of novel antagonists of leukotriene B4. Tetrahedron Lett 1988; 29: 143–146.Google Scholar
  148. 146.
    Fels AOS, Pawlowski NA, Cramer EB, King TKC, Cohn ZA, Scott WA. Human alveolar macrophages produce leukotriene B4. Proc Natl Acad Sci 1982; 79: 7866–7870.PubMedGoogle Scholar
  149. 147.
    Ferreri NR, Howland WC, Spiegelberg HL. Release of leukotriene C4 and B4 and prostaglandin E2 from human monocytes stimulated with aggregated IgG, IgA, and IgE. J Immunol 1986; 136: 4188–4193.PubMedGoogle Scholar
  150. 148.
    Williams JD, Robin J-L, Lewis RA, Lee TH, Austen KF. Generation of leukotrienes by human monocytes pretreated with cytochalasin B and stimulated with formyl-methionyl-leucyl-phenylalanine. J Immunol 1986; 136: 642–648.PubMedGoogle Scholar
  151. 149.
    Freeland HS, Schleimer RP, Schulman ES, Lichtenstein LM, Peters SP. Generation of leukotriene B4 by human lung fragments and purified human lung mast cells. Am Rev Respir Dis 1988; 138: 389–394.PubMedGoogle Scholar
  152. 150.
    Lin AH, Morris J, Wishka DG, Gorman RR. Novel molecules that antagonize leukotriene B4 binding to neutrophils. Ann NY Acad Sci 1988; 524: 196–200.PubMedGoogle Scholar
  153. 151.
    Lawson CF, Wishka DG, Morris J, Fitzpatrick FA. Receptor antagonism of leukotriene B4 myotropic activity by the 2,6 disubstituted pyridine analog U-75302: characterization on lung parenchyma strips. J Lipid Mediators 1989; 1: 3–12.Google Scholar
  154. 152.
    Kishikawa K, Matsunaga N, Maruyama T, Seo R, Toda M, Miyamoto T, Kawasaki, A. ONO-LB-457: A novel and orally active leukotriene B4 receptor antagonist. In: B. Samuelsson, P. W. Ramwell, R. Paoletti, G. Folco and E. Granström, editors. Advances in Prostaglandin, Thromboxane and Leukotriene Research, vol. 21A. Raven Press, Ltd., New York, 1991: 407–410.Google Scholar
  155. 153.
    Huang F-C, Chan W-K, Warns, JD, Morrissette MM, Moriarty KJ, Chang MN, Travis JJ, Mitchell LS, Nuss GW, Sutherland CA. 4-[-[methyl(2-phenethyl)amino]-2-oxoethyl]-8-(phenylmethoxy)-2-naphthalenecarboxylic acid: A high affinity, competitive, orally active leukotriene B4 receptor antagonist. J Med Chem 1992; 35: 4253–4255.PubMedGoogle Scholar
  156. 154.
    Daines RA, Chambers PA, Eggleston DS, Foley JJ, Griswold DE, Haltiwanger RC, Jakas DR, Kingsbury WD, Martin LD, Pendrak I, Schmidt DB, Tzimas MN, Sarau HM. (E)-3-[[[[6-(2-Carboxyethenyl)-5-[[8-(4-methoxyphenyl)octyl]-2-pyridinyl]-methyl]-thio]methyl] benzoic acid and related compounds: High affinity leukotriene B4 receptor antagonists. J Med Chem 1994; 37: 3327–3336.PubMedGoogle Scholar
  157. 155.
    Tsai BS, Keith RH, Villani-Price D, Kachur JF, Yang DC, Djuric SW, Yu S. The in vitro pharmacology of SC-51146: A potent antagonist of leukotriene B4 receptors. J Pharmacol Exp Ther 1994; 268: 1499–1505.PubMedGoogle Scholar
  158. 156.
    Sawyer JS, Schmittling EA, Bach NJ, Baker SR, Froelich LL, Saussy Jr DL, Marder P, Jackson WT. Structural analogues of LY292728, a highly potent xanthone dicarboxylic acid leukotriene B4 receptor antagonist: spatial positioning of the secondary acid group. Bioorg Med Chem Letts 1994; 17: 2077–2082.Google Scholar
  159. 157.
    Cohen N, Yagaloff KA. Recent progress in the development of leukotriene B4 antagonists. Curr Opin Invest Drugs 1994; 3: 13–22.Google Scholar
  160. 158.
    Torphy TJ, Newton JF, Wasserman MA, Vickery-Clark L, Osborn RR, Bailey LS, Yodis LAP, Underwood DC, Hay DWP. The bronchopulmonary pharmacology of SK&F 104353 in anesthetized guinea pigs: demonstration of potent and selective antagonism of responses to peptidoleukotrienes. J Pharmacol Exp Ther 1989; 249: 430–437.PubMedGoogle Scholar
  161. 159.
    Osborn RR, Hay DWP, Wasserman MA, Torphy TJ, SKandF 104353, a selective leukotriene receptor antagonist, inhibits leukotriene D4-and antigen-induced bronchoconstriction in cynomolgus monkeys. Pulm Pharmacol 1992; 5: 153–157.PubMedGoogle Scholar
  162. 160.
    Turner CR, Smith WB, Andresen CJ, Swindell AC, Watson JW, Leukotriene D4 receptor antagonism reduces airway hyperresponsiveness in monkeys. Pulm Pharmacol 1994; 7: 49–58.PubMedGoogle Scholar
  163. 161.
    Abraham WM, Stevenson JS, Garrido R. The effect of an orally active leukotriene (LT) D4 antagonist WY-48,252 on LTD4 and antigen-induced bronchoconstrictions in allergic sheep. Prostaglandins 1988; 35: 733–745.PubMedGoogle Scholar
  164. 162.
    Tomoika K, Garrido R, Stevenson JS, Abraham WM. The effect of an orally active leukotriene (LT) antagonist YM-16638 on antigen-induced early and late airway responses in allergic sheep. Prostaglandins, Leukotrienes and Essential Fatty Acids 1989; 36: 43–47.Google Scholar
  165. 163.
    Sheard P, Lee TB, Tattersall ML. Further studies on the SRS-A antagonist FPL 55712. Monogr Allergy 1977; 12: 245–249.PubMedGoogle Scholar
  166. 164.
    Sheard P, Holroyde MC, Bantick JR, Lee TB. SRS-A antagonists. In: Buckle DR, editor. Development of Anti-asthma Drugs. London: Butterworth, 1984: 133–158.Google Scholar
  167. 165.
    Mead B, Patterson LH, Smith DA. The disposition of FPL 55712 acid (7-[3(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl-4H-benzopyran-2-carboxylic acid) in rat and dog. J Pharm Pharmacol 1981; 33: 682–684.PubMedGoogle Scholar
  168. 166.
    Holroyde MC, Cole M Altounyan REC, Dixon M, Elliott EV. Bronchoconstriction produced in man by leukotrienes C and D. Lancet 1981; 1: 17–18.Google Scholar
  169. 167.
    Lee TH, Walport MJ, Wilkinson AH, Turner-Warwick M, Kay AB. Slow-reacting substance of anaphylaxis antagonist FPL 55712 in chronic asthma. Lancet 1981; 2: 304–305.PubMedGoogle Scholar
  170. 168.
    Ahmed T, Greenblatt W, Birch S, Marchette B, Wanner A. Abnormal mucocilliary transport in allergic patients with antigen-induced bronchospasm: Role of slow reacting substance of anaphylaxis. Am Rev Respir Dis 1981; 124: 110–114.PubMedGoogle Scholar
  171. 169.
    Chasin M, Scott C. Inhibition of cyclic nucleotide phosphodiesterase by FPL 55712, an SRS-A antagonist. Biochem Pharmacol 1978; 27: 2065–2067.PubMedGoogle Scholar
  172. 170.
    Casey FB, Appleby BJ, Buck DC. Selective inhibition of the lipoxygenase metabolic pathway of arachidonic acid by the SRS-A antagonist, FPL 55712. Prostaglandins 1983; 25: 1–11.PubMedGoogle Scholar
  173. 171.
    Welton AF, Hope WC, Tobias LD, Hamilton JG. Inhibition of antigen-induced histamine release and thromboxane synthase by FPL 55712, a specific SRS-A antagonist? Biochem Pharmacol 1981; 30: 1378–1382.PubMedGoogle Scholar
  174. 172.
    Barnes N, Piper PJ, Costello J. The effect of an oral leukotriene antagonist L-649,923 on histamine and leukotriene D4-induced bronchoconstriction in normal man. J Allergy Clin Immunol 1987; 79: 816–821.PubMedGoogle Scholar
  175. 173.
    Phillips GD, Rafferty P, Robinson C, Holgate ST. Dose-related antagonism of leukotriene D4-induced bronchoconstriction by p.o. administration of LY-171883 in nonasthmatic subjects. J Pharmacol Exp Ther 1988; 246: 732–738.PubMedGoogle Scholar
  176. 174.
    Fuller RW, Black PN, Dollery CT. Effect of the oral leukotriene D4 antagonist LY171883 on inhaled and intradermal challenge with antigen and leukotriene D4 in atopic subjects. J Allergy Clin Immunol 1989; 83: 939–944.PubMedGoogle Scholar
  177. 175.
    Smith LJ, Geller S, Ebright L, Glass M, Thyrum PT. Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1990; 141: 988–992.PubMedGoogle Scholar
  178. 176.
    Kips J, Joos G, Pauwels R, Van Der Straeten M, Delepeleire I, Williams V, Margolskee D. MK-571 (L-660.771): A potent LTD4 antagonist in asthmatic men. Am Rev Respir Dis 1990; 141: A117.Google Scholar
  179. 177.
    Kips J, Margolskee D, Delepeleire I, Joos G, Williams V, Buntinx A, Pauwels R. MK-0679 is a potent and selective LTD4 antagonist in asthmatic men. Am Rev Respir Dis 1991; 143: A599.Google Scholar
  180. 178.
    Evans JM, Piper PJ, Costello JF. The pharmacological profile of SKandF 104353-Z2, a potent, selective inhaled antagonist of cysteinyl leukotrienes, in normal man. In: Samuelsson B, editor. Advances in Prostaglandins, Thromboxane and Leukotriene Research, vol. 21. New York: Raven Press, Ltd., 1990: 469–472.Google Scholar
  181. 179.
    Dinh Xuan AT, Regnard J, Similowski T, Rey J, Marsac J, Lockhart A. Effects of SK&F 104353, a leukotriene receptor antagonist, on the bronchial responses to histamine in subjects with asthma: A comparative study with terfenadine. J Allergy Clin Immunol 1990; 85: 865–871.Google Scholar
  182. 180.
    Spencer DA, Evans JM, Green SE, Piper PJ, Costello JF. Participation of the cysteinyl leukotrienes in the acute bronchoconstrictor response to inhaled platelet activating factor in man. Thorax 1991; 46: 441–445.PubMedGoogle Scholar
  183. 181.
    Voelkel NF, Worthen S, Reeves JT, Henson PM, Murphy RC. Nonimmunological production of leukotrienes induced by platelet-activating factor. Science 1982; 218: 286–288.PubMedGoogle Scholar
  184. 182.
    Bonnet J, Thibaudeau D, Bessin P. Dependency of PAF-acether induced bronchospasm on the lipoxygenase pathway in the guinea pig. Prostaglandins 1983; 26: 457–466.PubMedGoogle Scholar
  185. 183.
    Hui K, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991; 337: 1062–1063.PubMedGoogle Scholar
  186. 184.
    Finnerty JP, Wood-Baker R, Thomson H, Holgate ST. Role of leukotrienes in exercise-induced asthma. Am Rev Respir Dis 1992; 145: 746–749.PubMedGoogle Scholar
  187. 185.
    Dahlén B, Zetterström, Björk T, Dahlén S-E. The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir. J 1994; 7: 324–331.PubMedGoogle Scholar
  188. 186.
    Makker HK, Lau LC, Thomson HW, Binks SM, Holtage ST. The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993; 147: 1413–1418.PubMedGoogle Scholar
  189. 187.
    O’Shaughnessy KM, Taylor IK, O’Connor B, O’Connell F, Thomson H, Dollery CT. Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis 1993; 147: 1431–1435.PubMedGoogle Scholar
  190. 188.
    Joos GF, Kips JC, Pauwels RA, van der Straeten ME. The effect of aerosolized SK&F 104353-Z2 on the bronchoconstrictor effect of leukotriene D4 in asthmatics. Pulm Pharmacol 1991; 4: 37–42.PubMedGoogle Scholar
  191. 189.
    Ford-Hutchinson AW. Regulation of the production and action of leukotrienes by MK-571 and MK-886. In: Samuelsson B, Ramwell PW, Paoletti R, Folco G, Granström E, editors. Advances in Prostaglandin. Thromboxane and Leukotriene Research, vol. 21A. New York: Raven Press, Ltd., 1991: 9–16.Google Scholar
  192. 190.
    Gaddy J, Bush RK, Margolskee D, Williams UC, Busse W. The effects of a leukotriene D4 (LTD4) antagonist (MK-571) in mild to moderate asthma. J Allergy Clin Immunol 1990; 85: A187.Google Scholar
  193. 191.
    Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O’Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med 1990; 323: 1736–1739.PubMedGoogle Scholar
  194. 192.
    Wahedna I, Wisniewski AS, Tattersfield AE. Effect of RG 12525, an oral leukotriene D4 antagonist, on the airway response to inhaled leukotriene D4 in subjects with mild asthma. Br J Clin Pharmacol 1991; 32: 512–515.PubMedGoogle Scholar
  195. 193.
    Lammers J-W, Van Daele P, Van den Elshout FMJ, Decramer M, Buntinx A, De Lepeleire I, Friedman B. Bronchodilator properties of an inhaled leukotriene D4 antagonist (Verlukast-MK-0679) in asthmatic patients. Pulm Pharmacol 1992; 5: 121–125.PubMedGoogle Scholar
  196. 194.
    Dahlén B, Margolskee, DJ, Zetterström O, Dahlén S-E. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 1993; 48: 1205–1210.PubMedGoogle Scholar
  197. 195.
    Ellis JL, Undem BJ. Role of cysteinyl-leukotrienes and histamine in mediating intrinsic tone in isolated human bronchi. Am J Respir Crit Care Med 1994; 149: 118–122.PubMedGoogle Scholar
  198. 196.
    Aalbers R, De Monchy JGR. Cysteinyl-leukotriene receptor antagonist, bronchoconstriction, and airway hyperreactivity. Lancet 1991; 338: 445.PubMedGoogle Scholar
  199. 197.
    Taylor IK, O’Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991; 337: 690–694.PubMedGoogle Scholar
  200. 198.
    Dahlén S-E, Dahlén B, Eliasson E, Johansson H, Björck T, Kumlin M, Boo K, Whitney J, Binks S, King B, Stark R, Zetterström O. Inhibition of allergic bronchoconstriction in asthmatics by the leukotriene-antagonist ICI-204,219. In: Samuelsson B, Ramwell PW, Paoletti R, Folco G, Granström E, editors. Advances in Prostaglandin, Thromboxane, and Leukotriene Research, vol. 21A. New York: Raven Press, Ltd., pp. 1991: 461–464.Google Scholar
  201. 199.
    Findley SR, Barden JM, Easley CB, Glass M. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992; 89: 1040–1045.Google Scholar
  202. 200.
    Britton JR, Hanley SP, Tattersfield AE. The effect of an oral leukotriene D4 antagonist L-649,923 on the response to inhaled antigen in asthma. J Allergy Clin Immunol 1987; 79: 811–816.PubMedGoogle Scholar
  203. 201.
    Rasmussen JB, Eriksson L-O, Andersson K-E. Reversal and prevention of airway response to antigen challenge by the inhaled leukotriene D4 antagonist (L-648,051) in patients with atopic asthma. Allergy 1991; 46: 266–273.PubMedGoogle Scholar
  204. 202.
    Bel EH, Timmers MC, Dijkman JH, Stahl EG, Sterk PK. The effect of an inhaled leukotriene antagonist, L-648,051, on early and late asthmatic reactions and subsequent increase in airway responsiveness in man. J Allergy Clin Immunol 1990; 85: 1067–1075.PubMedGoogle Scholar
  205. 203.
    Hendeles L, Davison D, Blake K, Harman E, Cooper R, Margolskee D. Leukotriene D4 is an important mediator of antigen-induced bronchoconstriction: attenuation of dual response with MK-571, a specific LTD4 receptor antagonist. J Allergy Clin Immunol 1990; 85: 197A.Google Scholar
  206. 204.
    Taki F, Suzuki R, Torii K, Matumoto S, Taniguchi H, Takagi K. Reduction of the severity of bronchial hyperresponsiveness by the novel leukotriene antagonist 4-Oxo-8-[4-(4-phenyl-butoxy)benzoylamino]-2-(tetrazol-5yl)-4H-1-benzopyran hemihydrate. Arzneim Forsch Drug Res 1991; 44: 330–333.Google Scholar
  207. 205.
    Yamai T, Watanabe S, Motojima S, Fuduka T, Makino S. The significance of leukotriene in antigen-induced late asthmatic response. Am Rev Respir Dis 1989; 139: A462.Google Scholar
  208. 206.
    Creticos PS, Bodenheimer S, Albright A, Lichtenstein LM, Norman PS. Effects of an inhaled leukotriene antagonist on bronchial challenge with antigen. J Allergy Clin Immunol 1989; 83: 187.Google Scholar
  209. 207.
    Eiser N, Hayhurst M, Denman W. The contribution of histamine and leukotriene to the production of early and late asthmatic responses to antigen. Am Rev Respir Dis 1989; 139: A462.Google Scholar
  210. 208.
    Hamid M, Rafferty P, Holgate ST. The inhibitory effect of terfenadine and flurbiprofen on early and late-phase bronchoconstriction following allergen challenge in atopic asthma. Clin Exp Allergy 1990; 20: 261–267.PubMedGoogle Scholar
  211. 209.
    Naclerio RM, Kagey-Sobotka A, Lichtenstein LM, Freidhoff L, Proud D. Terfenadine, an H1 antihistamine, inhibits histamine release in vivo in the human. Am Rev Respir Dis 1990; 142: 167–171.PubMedGoogle Scholar
  212. 210.
    Kay AB. Asthma and inflammation. J Allergy Clin Immunol 1991; 87: 893–910.PubMedGoogle Scholar
  213. 211.
    Busse W. Mechanisms of inflammation and their therapeutic implications in the asthmatic patient. Ann Allergy 1992; 69: 261–266.PubMedGoogle Scholar
  214. 212.
    Robuschi M, Riva E, Fuccella LM, Vida E, Barnabe R, Rossi M, Gambaro G, Spagnotto S, Bianco S. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353). A double-blind study versus disodium cromoglycate and placebo. Am Rev Respir Dis 1992; 145: 1285–1288.PubMedGoogle Scholar
  215. 213.
    Torphy TJ, Faiferman I, Gleason JG, Hall RF, Lewis MA, Broom C, Helfrich HM, Newton JF, Hay DWP. The preclinical and clinical pharmacology of SK&F 104353, a potent and selective peptidoleukotriene receptor antagonist. Advances in the Understanding and Treatment of Asthma, Annals NY Acad Sci, 1991; 157-167.Google Scholar
  216. 214.
    Israel E, Juniper EF, Callaghan JT, Mathur PN, Morris MM, Dowell AR, Enas GG, Hargreave FE, Drazen JM. Effect of a leukotriene antagonist, LY 171883, on cold air-induced bronchoconstriction in asthmatics. Am Rev Respir Dis 1989; 140: 1348–1353.PubMedGoogle Scholar
  217. 215.
    Christie PE, Smith CM, Lee TH. The potent and selective SRS-A leukotriene antagonist, SKandF 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991; 144: 957–958.PubMedGoogle Scholar
  218. 216.
    Dahlén B. Kumlin M, Margolskee DJ, Larsson C, Blomqvist H, Williams VC, Zetterström O, Dahlén, S-E. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin and aspirin-sensitive asthmatics. Eur Respir J 1993; 6: 1018–1026.PubMedGoogle Scholar
  219. 217.
    Yamamoto H, Nagata M, Kuramitsu K, Tabe K, Kiuchi H, Sakamoto Y, Yamamoto K, Dohi Y. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 1994; 150: 254–257.PubMedGoogle Scholar
  220. 218.
    Cloud ML, Enas GC, Kemp J, Platts-Mills T, Altman LC, Townley R, Tinkelman D, King T Jr, Middleton E, Scheffer AL, McFadden ER Jr, Farlow DS. A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am Rev Respir Dis 1989; 140: 1336–1339.PubMedGoogle Scholar
  221. 219.
    Spector SL, Smith LJ, Glass M, Accolate Asthma Trialists Group. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 618–623.PubMedGoogle Scholar
  222. 220.
    Silbaugh SS, Stengel PW, Williams GD, Herron DK, Gallagher P, Baker SR. Effects of leukotriene B4 inhalation. Airway sensitization and lung granulocyte infiltration in the guinea pig. Am Rev Respir Dis 1987; 136: 930–934.PubMedGoogle Scholar
  223. 221.
    O’Driscoll BR, Cromwell O, Kay AB. Sputum leukotrienes in obstructive airways diseases. Clin Exp Immunol 1984; 55: 397–404.PubMedGoogle Scholar
  224. 222.
    Lam S, Chan H, LeRiche JC, Chan-Yeung M, Salari H. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol 1988; 81: 711–717.PubMedGoogle Scholar
  225. 223.
    Shindo K, Matsumoto Y, Hirai Y, Sumitomo M, Amano T, Miyakawa K, Matsumura M, Mizuno T. Measurement of leukotriene B4 in arterial blood of asthmatic patients during wheezing attacks. J Intern Med 1990; 228: 91–96.PubMedGoogle Scholar
  226. 224.
    Freeland HS, Pipkorn U, Schleimer RP, Bascom R, Lichtenstein LM, Naclerio, RM, Peters SP. Leukotriene B4 as a mediator of early and late reactions to antigen in humans: The effect of systemic glucocorticoid treatment in vivo. J Allergy Clin Immunol 1989; 83: 634–642.PubMedGoogle Scholar
  227. 225.
    Richards IM, Griffin RL, Oostveen JA, Morris J, Wishka DG, Dunn CJ. Effect of the selective leukotriene B4 antagonist U-75302 on antigen-induced bronchopulmonary eosinophilia in sensitized guinea pigs. Am Rev Respir Dis 1989; 140: 1712–1716.PubMedGoogle Scholar
  228. 226.
    Stout BK, Johnson HG, Inhibition of late phase bronchoconstriction and eosinophilia in Ascaris ova sensitized primates by steroids, an LTB4 antagonist and lazaroid. Am Rev Respir Dis 1990; 141: A473.Google Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 1995

Authors and Affiliations

  • Douglas W. P. Hay
    • 1
  • David Raeburn
    • 2
  1. 1.Department of Pulmonary PharmacologySmithKline Beecham PharmaceuticalsKing of PrussiaUSA
  2. 2.Department of InflammationRhône-Poulenc Rorer, Inc.CollegevilleUSA

Personalised recommendations